Background/Purpose: The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its oral tablet form. Methods: We used the Markov model to estimate total additional lifetime costs and qualityadjusted life years (QALYs) gained with deferasirox versus deferoxamine in patients with transfusion-dependent thalassemia. Patients were assumed to be 2 years of age at initiation of chelation therapy. Clinical outcomes in terms of morbidity and mortality from associated complications and life expectancy for the study population were estimated using the databases of the Bureau of National Health Insurance and the Health and Vital Statistics of Taiwan. Treatment costs were based on analyses of health insurance claims for patients with transfusion-dependent thalassemia. Utilities in terms of quality of life were also included in the model. The incremental costeutility ratio of deferasirox versus deferoxamine was defined by the ratio of the difference in expected lifetime costs to the difference in QALYs. One-way sensitivity analyses were performed to examine the robustness of the results to key assumptions.
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Introduction
Thalassemia has a very wide clinical range of severity from transfusion dependency beginning in infancy to a mild condition requiring little if any medical intervention. Thalassemia major is the severe form of the disease, presenting with transfusion-dependent anemia, generally in the first year of life. The mainstay of supportive treatment is regular blood transfusions accompanied by iron-chelating therapy. 1 With multiple transfusions, excess iron appears in the plasma that surpasses the capability of the body to safely store and handle it. Excess iron can potentially penetrate cells in the liver, heart, endocrine glands, and other organs and cause progressive tissue damage by generating hydroxyl free radicals, which cause oxidative stress. 2e5 The human body has a limited capacity to control iron by tight binding of plasma iron to transferrin, which becomes completely saturated in patients with an excessive iron load. As a consequence, non-transferrin-bound iron, including labile plasma iron, is generated, and free radical formation is accelerated in several organs and tissues. Iron overload is frequently associated with transfusion therapy in patients with thalassemia major, 2,6 myelodysplastic syndromes, 7 and sickle cell disease. 8 If untreated, accumulation of iron in various organs may result in certain fatal complications, including cardiac dysfunction, diabetes, liver disease, hypogonadism, hypothyroidism, and hypoparathyroidism.
Other than transferrin, the human body itself has no physiological mechanism for removing excess iron. Therefore, iron chelation therapy is currently the only means of managing iron overload in transfusion-dependent patients. Deferoxamine has been the standard therapeutic option for thalassemia for the past 40 years. This drug effectively maintains iron stores at levels that are normal to nearnormal, reduces organ damage, and increases life expectancy in patients with thalassemia. 9 However, the poor bioavailability and short plasma elimination half-life of deferoxamine require that it be administered as a subcutaneous or intravenous infusion over a period of 8e12 hours five to seven times per week. Therefore, patient compliance is suboptimal because of the discomfort and demands associated with the administration regimen. 10, 11 Deferiprone is an orally absorbed iron chelator first licensed in India, followed by the European Union and other countries outside the United States and Canada, including many countries in Asia in the late 1990s. The elimination half-life of deferiprone is 2e3 hours in most patients, and therefore it is given at a dose of 25 mg/kg body weight three times a day for a total daily dose of 75 mg/kg body weight. By combining deferiprone with deferoxamine, an increased proportion of patients may achieve iron balance and improved myocardial iron removal when compared with monotherapy with either drug. 12e17 However, several adverse and potentially severe events associated with deferiprone, including agranulocytosis [absolute neutrophil count (ANC) < 500/mm 3 ], neutropenia (ANC < 1500/mm 3 ), and arthropathy, may have limited its use in routine clinical practice. 18, 19 Because of this, only a limited number of patients with transfusion-dependent thalassemia in Taiwan were on the deferiprone regimen before the introduction of deferasirox, partly due to its special application to the Bureau of National Health Insurance (BNHI) and unwanted adverse effects.
Deferasirox, a newer oral iron chelator, was approved by the US Food and Drug Administration in October 2005 for firstline use in adults and children (age ! 2 years) with chronic iron overload that is due to blood transfusions. 20 It has now been approved in most Asian countries, including Malaysia, Singapore, Taiwan, and Thailand. 2 This drug is orally bioavailable, and its terminal elimination half-life is between 8 and 16 hours, allowing once-daily administration. 21 In Taiwan, deferoxamine has been the mainstay of iron chelation therapy for patients with transfusion-dependent thalassemia since its introduction in the 1960s. With the approval of deferasirox in many countries worldwide, including Taiwan in the 2000s, some issues have appeared regarding differences in compliance and quality of life associated with oral (deferasirox) versus infusional (deferoxamine) therapy. A higher acquisition cost of deferasirox is anticipated because of potentially better drug compliance, with the trade-off of reduced costs for infusional therapy and for the treatment of complications of iron overload in patients with poorly controlled thalassemia.
Therefore, from a healthcare system perspective, the aim of this study was to evaluate the costeutility of deferasirox versus deferoxamine in patients with transfusion-dependent thalassemia given the similar treatment efficacy and safety of deferasirox and deferoxamine. 22, 23 We assumed that patients with transfusiondependent thalassemia started iron chelation therapy at the age of 2 years. Therefore, the objective of this study was to compare lifetime clinical outcomes and economic impacts between deferoxamine and deferasirox for a cohort of 2-year-old patients with transfusion-dependent thalassemia using a simulation modeling method.
Methods

Overview
The subjects of economic evaluation in this study, deferoxamine and deferasirox, have comparable treatment efficacies for reducing the incidence of iron overload-related complications in patients with transfusion-dependent thalassemia. Because of different administration methods, the once-daily oral form of deferasirox is, however, expected to have better drug compliance than the subcutaneous or intravenous form of deferoxamine. Therefore, patients treated with deferasirox are expected to show a lower incidence of complications than those treated with deferoxamine.
In addition to the potential benefits described above, deferasirox is also, because of its oral form, expected to provide a better quality of life for patients than treatment with deferoxamine. Therefore, after adjusting for qualityof-life parameters, patients treated with deferasirox are still expected to show better quality-adjusted life years (QALYs) than those treated with deferoxamine.
With cost and outcome indicators available, a simple costeutility ratio can be calculated for both chelation therapies, and a comparison can be made. In this study, the costeutility ratio was calculated by dividing total treatment costs by total QALYs gained, with both costs and life years discounted.
Although several long-term benefits are anticipated with using deferasirox as a chelation agent, the unit cost of the newly introduced deferasirox is much higher than that of deferoxamine. To provide a full spectrum of information to decision-makers, it is better to have an indicator that incorporates the various parameters presented above. Based on the above statements, this study of economic evaluation intended to answer the question: "How much does it cost to obtain an additional QALY for patients with transfusion-dependent thalassemia using deferasirox?"
Study design
To answer this study question, a pharmaco-economic approach was adopted. Specifically, the study design was categorized as a "costeutility analysis". 24 For the proposed study, a simulation modeling method was used to project lifetime outcomes and costs for the population of interest while incorporating quality-of-life parameters.
Study population and assumptions
The study population was defined as patients who had a primary diagnosis of thalassemia [International Classification of Diseases, 9th revision (ICD-9) code 282.4] and who received regular blood transfusions (and who therefore had a certification of catastrophic illness and chronic disease) according to the claims database of the BNHI of Taiwan. It was assumed that patients started iron chelation therapy at the age of 2 years.
Study model and parameters used in the model
For chronic or complex diseases, it is best to incorporate a decision analysis model into the analysis that allows researchers to incorporate changes in health states over time. The Markov model is a decision analysis model that enables researchers to track changes in the quality of life, the quantity of life, and the medical cost of a disease over time when different health interventions are applied. 24, 25 In the Markov model, each patient in a hypothetical cohort is essentially treated as an individual. Each patient can be assigned different characteristics and risk factors at the beginning. As patients age, the model records the changes in their health status. When a patient develops a medical event (e.g., iron overload-related cardiac disease or diabetes mellitus), any associated costs incurred and any change in health-related quality of life will be captured in the Markov model. Therefore, the Markov model is a powerful and accurate way of modeling the change in health states over time.
In this study, we used a Markov model that assigned various risk factors such as the type of iron chelation therapy, treatment compliance, and probabilities of associated complications to each individual of a hypothetical study population. The model then calculated clinical outcomes in terms of morbidity and mortality from associated complications and expected life expectancy for the study population.
We also added parameters of treatment costs and utility regarding quality of life to the model. In addition, by taking quality-of-life parameters into consideration, the life expectancies provided earlier were transformed to QALYs gained. QALYs are a measure of health outcome that adjusts life years for the quality of life during those years and provides a common unit for comparing health benefits across different diseases and/or interventions. QALYs are calculated by multiplying life years by utility values. Utility values are weights that represent preferences for different health states and range from 0.0 (death) to 1.0 (perfect health). 24 Finally, the study model provided a measure of the incremental costeutility ratio of the two medications. The incremental costeutility ratio of deferasirox versus deferoxamine was defined as the ratio of the difference (deferasirox minus deferoxamine) in expected lifetime costs to the difference (deferasirox minus deferoxamine) in QALYs.
Drug cost parameters
The unit costs per milligram were US$0.02 for deferoxamine and US$0.0607 for deferasirox. Prescribed dosages of deferasirox and deferoxamine were estimated to be 24.6 mg/kg/d, 7 days per week and 47.4 mg/kg/d, 5 days per week, respectively. 22 In addition, administering subcutaneous or intravenous infusion of deferoxamine incurs administration costs, including an infusion or intravenous service or infusion supplies (e.g., pumps). It was estimated that deferoxamine infusions cost US$141.1 per month for each patient. In contrast, because of its oral tablet form, the cost of administering deferasirox was assumed to be zero.
Treatment cost parameters associated with iron overload complications
There are five associated complications of iron overload: cardiac disease, diabetes mellitus, hypothyroidism, hypogonadism, and hypoparathyroidism. Annual treatment costs for each complication for each patient were required by the model to calculate the total lifetime treatment costs. To provide these parameters, we extracted patient data from the claims database of the BNHI. Data for the study population were collected from both the inpatient database from 1997 to 1999 and the outpatient database from 2000 to 2004. The data were identified by diagnostic codes for (1) cardiac disease, including cardiomyopathy (ICD-9 code 425.4), conduction disorders (ICD-9 code 426.10), cardiac dysrhythmias (ICD-9 code 427.9), and heart failure (ICD-9 code 428.0); (2) diabetes mellitus (ICD-9 code 250.00); (3) hypothyroidism (ICD-9 code 244.9); (4) hypogonadism (ICD-9 code 256.3 or 257.2); and (5) hypoparathyroidism (ICD-9 code 252.1). The treatment costs associated with each complication for each patient were calculated to obtain the annual average cost of each complication.
Compliance
Compliance with deferoxamine, which was estimated to be 50% in Taiwan, was derived from prior clinical data at National Taiwan University Hospital. 26 Because there has been no clinical experience with using deferasirox in Taiwan, we estimated the improvement in compliance based on data from a nonrandomized prospective study comparing the thrice-daily oral chelator deferiprone with deferoxamine. 27 Therefore, we conservatively estimated that the once-daily oral chelator deferasirox would improve compliance by 16% versus deferoxamine. Because of this assumption, we carried out a sensitivity analysis for this parameter.
Public health parameters
Because the dosage for each patient was determined by his or her weight, average weight by age was obtained from the National Survey of Nutrition and Vital Statistics conducted in Taiwan from 2001 to 2004. The model assumed that the probability of complications for the study population with perfect drug compliance would be the same as that for the general population, and that a lack of drug compliance would cause complications.
There were no data available in the public domain regarding the age-matched morbidity rate of these associated complications in Taiwan. Therefore, to obtain those figures, the database provided by the BNHI was used. The age-matched incidence rate of iron overload-related complications for the study population was obtained from the database.
In addition to morbidity, the study model also required the mortality rate after developing each complication to simulate the number of life years remaining. For that purpose, the age-matched mortality rate of each associated complication was retrieved from the database of the Health and Vital Statistics in Taiwan for the year 2004.
Other parameters and assumptions
Quality parameters are important in a costeutility study that requires adjustment for indicators (e.g., life years). Because deferasirox is administered in an oral form, there is no deterioration in the quality of life. In contrast, because deferoxamine is administered by injection, it is estimated that the quality of life for patients treated with deferoxamine is 28% less than that for patients who received deferasirox. 21 For patients with cardiac disease, their quality of life is estimated to be approximately 15% less than that for individuals without cardiac disease. 21, 28 For patients suffering from other complications, the quality of life is estimated to be 5% less than that for individuals without such complications. 24 In addition to the parameters described above, some important assumptions were adopted for this study model. The model assumed that individuals in the study population started iron chelation therapy at the age of 2 years and continued for their lifetime. In addition, both life years and costs were subject to an annual discount rate of 3%. 30 
Analysis plan
After obtaining the values for the parameters presented above, base-case analyses were then performed. The Markov model, which was calculated using the macro function of Microsoft Excel (Microsoft Corporation, Redmond, WA, USA), generates results of expected life years, QALYs, and expected medical costs regarding chelation therapy [drug and administration (deferoxamine only)] and iron overload-related complications in the study population for the two scenarios (treated with deferoxamine or with deferasirox). To obtain a complete picture of the simulation model, various one-way sensitivity analyses were also conducted by assigning the range of important parameters of the Markov model. Results from the sensitivity analyses can add to the information base on which policy is made by health authorities or clinicians.
Results
Costs of treatment for iron overload-related complications
Both outpatient data from 2000 to 2004 and inpatient data from 1997 to 1999 that were extracted from the BNHI database were used to calculate the treatment costs of iron overload-related complications. Using the diagnostic code ICD-9-CM as the identifier, the medical records of patients with transfusion-dependent thalassemia were identified from the database. The numbers of patients with complications and related visits to a healthcare provider each year are shown in Table 1 .
There were increasing numbers of patients with transfusion-dependent thalassemia whose medical costs had been reimbursed by BNHI during the data years available (Table 1 ). In addition, we observed that the yearly average frequency of outpatient visits increased from 10.32 times per patient to 12.42 times per patient from 2000 to 2004; however, the frequency of inpatient visits seemed relatively stable from 1997 to 1999 (Table 1) .
We examined five major iron overload-related complications in the study population. The data were identified by the diagnostic codes for (1) cardiomyopathy, conduction disorders, cardiac dysrhythmias, or heart failure; (2) diabetes mellitus; (3) hypothyroidism; (4) hypogonadism; and (5) hypoparathyroidism. An analysis of visit and patient numbers corresponding to the individual complication for each data year is presented in Table 2 . Cardiac disease and diabetes mellitus were the most common complications in the study population, and they were the most common causes of outpatient and inpatient visits during the data years. Hypogonadism, hypothyroidism, and hypoparathyroidism accounted for fewer outpatient and inpatient visits. Of note, few patients sought medical attention as outpatients for hypoparathyroidism, and no patients were hospitalized for hypoparathyroidism.
Because each record from the database represents an outpatient or inpatient visit, the total amount paid is shown in each record and indicates the amount that the BNHI reimbursed to the healthcare provider for medical services. By using the diagnostic code ICD-9-CM as the identifier, the medical records of patients with iron overload-related complications were identified and extracted from the database, and the yearly average treatment costs were calculated. However, because the patient numbers for individual complications were different in each data year, the yearly average treatment costs needed to be weighted by the number of patients each year in order to arrive at a weighted average treatment cost for outpatient and inpatient services. Table 3 shows that the weighted yearly outpatient average costs for treating the iron overload-related complications of diabetes mellitus were US$1476, followed by US$1188 for cardiac disease, US$975 for hypothyroidism, US$605 for hypogonadism, and US$293 for hypoparathyroidism. The weighted yearly inpatient average costs for treating the iron overload-related complications of cardiac disease were US$978, followed by US$594 for diabetes mellitus, US$408 for hypogonadism, and US$259 for hypothyroidism. No patients were hospitalized for hypoparathyroidism.
The yearly average treatment costs for each complication were calculated by combining the weighted average treatment costs of both outpatient and inpatient services. The yearly average treatment costs for iron overload-related cardiac disease were US$2166, followed by US$2070 for diabetes mellitus, US$1234 for hypothyroidism, US$1013 for hypogonadism, and US$293 for hypoparathyroidism. These results were incorporated into the study model.
Base-case analyses
After entering all the required parameters onto the worksheet of the study model, base-case analyses were performed. The major results of the base-case analyses are shown in Table 4 . Over the 50-year time frame of the model, the model predicted that patients treated with However, the incidence of hypogonadism in patients treated with deferasirox was 2.7% more than that in patients treated with deferoxamine (18.0% vs. 15.3%). Iron overload-related cardiac disease was the major cause of death in deferasirox-and deferoxamine-treated patients (99.1% vs. 99.3%). Time to develop cardiac disease was projected to be increased by 2.2 years with deferasirox. The base-case results showed that if the study population had been treated with deferasirox, each patient would be expected to gain more life years as well as QALYs than if they had been treated with deferoxamine. The model estimated that patients treated with deferasirox would gain 2.1 additional life years (undiscounted) compared with those who had been treated with deferoxamine (15.3 life years vs. 13.2 life years). After adjusting for quality-of-life parameters, deferasirox yielded 3.2 additional QALYs (undiscounted; 11.7 QALYs vs. 8.5 QALYs). On a discounted basis, the gains in overall and qualityadjusted life expectancy with deferasirox versus deferoxamine were 1.3 life years and 2.3 QALYs.
Because of the better long-term clinical outcomes, deferasirox would reduce treatment costs over a lifetime for iron overload-related cardiac disease and diabetes mellitus by US$603 (US$11,110 vs. US$11,713) and US$1059 (US$8408 vs. US$9467), respectively. Because of higher drug costs (US$81,219 for deferasirox and US$34,330 for deferoxamine) that were partly offset by savings in administration costs for deferoxamine (US$9078) and, to a lesser degree, savings in the medical costs arising from the complications of cardiac disease (US$603) and diabetes mellitus (US$1059), patients treated with deferasirox would experience a much higher total lifetime cost than would those treated with deferoxamine. Therefore, the total lifetime costs were estimated to be US$103,288 per person treated with deferasirox versus US$66,997 per person treated with deferoxamine. The costeutility of deferasirox versus deferoxamine was therefore estimated to be US$15,596 per QALY gained.
Sensitivity analyses
There were several parameters that were subject to change, and therefore these were used in sensitivity analyses. Several one-way sensitivity analyses were performed using the incremental costeutility ratio as the primary outcome indicator for this study. Results of sensitivity analyses showed that when other parameters were held constant, the total costs for obtaining each additional QALY by using deferasirox (i.e., the costeutility ratio) were sensitive to the unit cost of deferasirox (Table 5) , the drug compliance with deferoxamine (Table 6) , the drug compliance change from deferoxamine to deferasirox (Table 7) , and the starting age of chelation therapy (Table 8) .
Among the four parameters used for sensitivity analyses, the unit costs of deferasirox showed the most dramatic influence on the costeutility ratio. For each change of US$0.01 of deferasirox per milligram, there was a difference of approximately US$6000 for obtaining each additional QALY. In comparison, when delaying the starting age of chelation therapy from 2 years to 5 years, there would be an increase of US$1383 for obtaining each additional QALY.
Discussion
Chelation therapy is the only treatment currently available for patients suffering from iron overload caused by transfusion. Although the treatment efficacies of the two currently available iron chelators, deferasirox and deferoxamine, were found to be equivalent, deferasirox was expected, because of its oral tablet form, to provide better clinical outcomes as a result of improved drug compliance and eventually better costeutility.
By using a population with thalassemia as the participants in our investigation, we compared various clinical outcomes and pharmaco-economic indicators between the two iron chelators with the aid of a Markov model and data from the claims database of the BNHI of Taiwan. The model estimated that the incidences of cardiac disease and diabetes, the most common iron overload-related complications in patients with transfusion-dependent thalassemia, were reduced by 0.2% and 13.7%, respectively, in patients treated with deferasirox. The time to development of cardiac disease was projected to be increased by 2.2 years with deferasirox. With this model, reduced morbidity and mortality incidence rates inevitably led to higher life years as well as QALYs for patients treated with deferasirox.
Because of higher unit drug costs and longer life years, patients treated with deferasirox are expected to experience a much higher total lifetime drug cost than would patients treated with deferoxamine. This prediction leads to a trade-off, such that the longer life years and better quality of life come at an increased treatment cost. The model estimated that treatment with deferasirox would result in an additional 2.3 QALYs at an additional expected lifetime cost of US$36,291, yielding a costeutility ratio of US$15,596 per QALY gained. This value is below the range that is considered to be acceptable in Taiwan (i.e., US$50,000e100,000 per QALY gained). 32, 33 The Taiwanese government has conducted a National Screening Program that began in 1993, and based on these data, the number of births of patients with thalassemia major has decreased 28 Assuming that there are three to six new cases of transfusion-dependent thalassemia in Taiwan per year, the financial burden of increased use of deferasirox in this population is small (i.e., ranging from US$46,788 to US$93,576).
In addition to the base-case analyses presented above, four parameters were used to perform sensitivity analyses against the indicator of incremental costs for obtaining an additional QALY: the unit cost of deferasirox, the drug compliance with deferoxamine, the change in drug compliance with a switch from deferoxamine to deferasirox, and the starting age of chelation therapy. The model found that the unit drug cost of deferasirox has the most dramatic impact on the incremental costeutility ratio. For each change of US$0.01 in the price of deferasirox per milligram, there was a difference of approximately US$6000 for obtaining each additional QALY. In addition, starting chelation therapy at an earlier age should result in a reduced lifetime treatment cost because delaying the starting age of chelation therapy from 2 years to 5 years is predicted to result in an increase of US$1383 for obtaining each additional QALY.
Limitations of this study
This study used a decision modeling approach, specifically the Markov model, to perform the analyses. Because the results of the base-case analyses are not derived from reallife experiences but from simulation with the best available parameters, they can serve only as a guide. To overcome the drawbacks posed by the decision model, we performed various sensitivity analyses to provide a full spectrum of information to decision-makers.
The study population comprised patients with transfusion-dependent thalassemia who were at high risk for iron overload. Therefore, the results of this study cannot be generalized to other populations who also require chelation therapy, such as patients with myelodysplastic syndrome or other chronic types of anemia. 29, 31 Also, we estimated the expected improvement in compliance with deferasirox versus deferoxamine to be approximately 16% based on a previous report 27 comparing compliance with deferiprone with that of deferoxamine. The estimate may be conservative, as compliance with a once-daily oral chelator (deferasirox) would be expected to be better than that with a thrice-daily oral chelator (deferiprone).
The other limitation of this study is due to the data source. The BNHI database served as the data source for parameters of treatment costs. Because the purpose of the BNHI database is to claim fees from the BNHI to reimburse healthcare providers, the construction of the database may not perfectly fit the needs of this study. For example, each medical record in the database represents one outpatient or inpatient visit. It is possible that one medical record may contain more than one diagnostic code. If there were more than one diagnostic code regarding iron overload-related complications in one record, it would be difficult to attribute the total costs of the record separately and specifically to individual complications. Therefore, some values of the parameters may not reflect the exact medical condition.
In addition, to collect information about the relevant parameters, we were granted use of the data in the nationwide health insurance claims database. During the time period of our research, however, only data for outpatient visits from 2000 to 2004 and inpatient visits from 1997 to 1999 were available. Nevertheless, we believe that the influence of the aforementioned limitations should be minimal because there has been no significant change in the treatment strategies for patients with transfusiondependent thalassemia in the last 20 years in Taiwan.
In conclusion, deferasirox has been shown to be safe and effective, similar to deferoxamine, in patients with transfusion-dependent thalassemia. Because of its method of administration, deferoxamine provides poor quality of life for patients and eventually affects long-term clinical outcomes. The newer iron chelator deferasirox is expected to overcome those drawbacks because it is in oral tablet form. The results of this study show that a marked improvement in drug compliance and a reduction in iron overload-related complications can be achieved by using deferasirox. However, because deferasirox has been licensed for use in Taiwan for fewer than 10 years, the longterm side effects and efficacy are not completely known and should be monitored closely.
In addition, expensive new technologies always pose financial considerations for decision-makers. The model estimated that treatment with deferasirox will result in an a When delaying the starting age of chelation therapy from 2 to 5 years, there would be an increase of US$1383 for obtaining each additional QALY. additional 2.3 QALYs at an additional expected lifetime cost of US$36,291, yielding a costeutility ratio of US$15,596 per QALY gained. Therefore, we suggest that, from a healthcare perspective, deferasirox should be considered for use in patients who require iron chelation therapy.
